Kenneth R LaMontagne Selected Research

1- (4- (6- amino- 5- (methoxyiminomethyl)pyrimidin- 4- yloxy)- 2- chlorophenyl)- 3- ethylurea

1/2009

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth R LaMontagne Research Topics

Disease

2	Neoplasms (Cancer) 01/2009 - 02/2006
1	Neoplasm Metastasis (Metastasis) 01/2009
1	Corneal Neovascularization 01/2009
1	Breast Neoplasms (Breast Cancer) 02/2006

Drug/Important Bio-Agent (IBA)

1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2009
1	1- (4- (6- amino- 5- (methoxyiminomethyl)pyrimidin- 4- yloxy)- 2- chlorophenyl)- 3- ethylureaIBA 01/2009
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2009
1	Erythropoietin FDA Link 02/2006
1	epoetin betaIBA 02/2006
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2006
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 02/2006

Therapy/Procedure

1	Therapeutics 02/2006